PDCD1 and cancer: The discovery that checkpoint inhibitor blockade, notably through the use of anti-PD-1 and anti-CTLA-4 antibodies, reinvigorates exhausted T cells was a landmark finding that ultimately changed the landscape of cancer therapy.